These firms would make great acquisitions for big drug companies looking to expand their cancer portfolios.   Read More

The Lightning Round is extended in this CNBC.com exclusive feature.   Read More

Plus, Cramer makes the call on Obama's health-care plans, smartphone data overload and more.   Read More

When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.    Read More

Following are the day’s biggest winners and losers. Find out why shares of Garmin and Ralph Lauren popped while Electronic Arts and Onyx Pharma dropped.   Read More

Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.    Read More

What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.    Read More

Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.    Read More